Clinical Trials Browser

Leukemia, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05809180 2023-04-20

Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients

Phase NA Recruiting

35 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02228512 2018-08-31

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Phase 1/2 Withdrawn

Lymphoid

Lymphoma, Primary Effusion

NCT02071888 2018-07-18

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

Phase 1 Completed

25 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma

NCT01078974 2016-07-25

Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

Phase 1 Terminated

7 enrolled 8 charts

Lymphoid

Waldenstrom Macroglobulinemia

Clinical Trials

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma

Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia